Please login to the form below
Kyowa Kirin
This page shows the latest Kyowa Kirin news and features for those working in and with pharma, biotech and healthcare.
CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
The European Medicines Agency’s (EMA) Comittee for Medicinal Products for Human Use (CHMP) has rejected Kyowa Kirin’s Parkinson’s disease drug Nouryant, despite the treatment being approved in the ... with Parkinson’s, an area which has had few
Latest news
-
GSK’s anti-BCMA drug leads crowded CHMP recommendations
Among other highlights from the meeting, Novartis scored a recommendation for its sickle cell therapy Adakveo (crizanlizumab) for the prevention of recurrent vaso-occlusive crises or pain crises, while Kyowa Kirin
-
SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease
Kyowa Kirin’s drug is the first treatment to target the underlying cause of XLH – Crysvita is an anti-FGF23 monoclonal antibody (mAb). ... Under this framework, eligible children in Scotland will be able to access Crysvita while Kyowa Kirin collects
-
GSK files anaemia drug daprodustat in Japan, its first market
If approved, daprodustat would be an oral alternative to erythropoiesis-stimulating agents (ESAs) such as Kyowa Kirin’s Espo (epoetin alfa) and biosimilars that have to be delivered by injection. ... Daprodustat – a hypoxia-inducible factor prolyl
-
Leo Pharma to market AstraZeneca’s brodalumab outside Europe
The rights to the psoriasis treatment are owned by Kyowa Kirin in Japan and other Asian countries.
-
Pfizer closes on EU approval of lung cancer drug Vizimpro
The two new biosimilars will join products from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit in an assault on AbbVie’s market share for the
More from news
Approximately 5 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Reaching patients and HCPs during the pandemic
execute a successful virtual launch if it is going to compete with drugs such as Inbrija (Acorda Therapeutics), Nourianz (Kyowa Kirin), and Ongentys (Neurocrine Biosciences).
-
Deal Watch March 2016
$110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.
-
Pharma deals in July 2015
AZ originally licensed the rights to the molecule from BioWa, a subsidiary of Kyowa Hakko Kirin, in all countries except Japan and certain countries in Asia. ... Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics
-
Pharma deals during July 2014
These deals rarely have financials attached. Amongst the collaborations announced during July was that between AZ and Kyowa Hakko Kirin (KHK) for a co-funded phase 1/1b immuno-oncology study
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
ProStrakan lines up new chairman for 2014
Japanese parent company Kyowa Hakko Kirin. ... and transitioned from being a small independent company into an important part of Kyowa Hakko Kirin.".
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
From Vision to Action: Medical Affairs’ Time to Lead is Now – Key Themes and Takeaways From the 2022 Medical Affairs Professional Society (MAPS) Global Annual Meeting
presented by Denise Chambley and Suzanna Lawrence (Amplity Health), Danie du Plessis (Kyowa Kirin), Jessica Nora (BioMarin Pharmaceutical), and Marco Taglietti (SCYNEXIS).
-
IGNIFI
Kyowa Kirin. Sobi. Theramex. Veriton Pharma. Vifor Pharma.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
